Search

Displaying results 3681 - 3690 of 10000 in total
  1. Drug

    MM-111

    go.drugbank.com/drugs/DB17983
    Investigational

    MM-111 is a novel bispecific antibody fusion protein that co-targets the the epidermal growth factor family receptor tyrosine kinases, ERBB2 and ERBB3.

  2. Drug

    Lasmiditan

    go.drugbank.com/drugs/DB11732
    ApprovedInvestigational

    Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019. … [sumatriptan]) have seen preferential use in the acute treatment of migraines due to their relatively favourable efficacy and safety.

  3. Drug

    Viomycin

    go.drugbank.com/drugs/DB06827
    Approved

    These drugs bind RNA in bacterial ribosomes and inhibit protein synthesis. Viomycin was derived from the actinomycete _Streptomyces puniceus_.

  4. Drug

    Eladocagene exuparvovec

    go.drugbank.com/drugs/DB16780
    ApprovedInvestigational

    [L43642] Eladocagene exuparvovec received EMA approval in July 2022. … [A253687] It was subsequently approved by the FDA in November 2024.[L51898,L51893]

    Categories: Complex Mixtures
  5. Drug

    Penicillium italicum

    go.drugbank.com/drugs/DB10811
    Approved

    Penicillium italicum extract is used in allergenic testing.

    Mixtures: Number Ten Mold Mixture, Number Ten Mold Mixture
  6. Drug

    Ciltacabtagene autoleucel

    go.drugbank.com/drugs/DB16738
    ApprovedInvestigational

    [A245854] Carvykti was first approved by the FDA in February 2022 for the treatment of relapsed or refractory multiple myeloma in treatment-experienced patients.[L40744] … [A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell lines, making it a choice target in the development

  7. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [A245159,L40114] In approximately 90% of cases, patients develop immunoglobulin M (IgM) autoantibodies towards the I antigen on erythrocytes - these antibodies react optimally at 4°C and are therefore … [A245154] Notably, none of these agents are approved for use in the treatment of CAD.

  8. Drug

    Tiratricol

    go.drugbank.com/drugs/DB03604
    ApprovedInvestigational

    [A274073] Tiratricol is currently being investigated in US clinical trials. … by chronic tissue thyrotoxicosis and abnormal neuronal development due to the impaired thyroid hormone uptake in the brain.

  9. Drug

    Sulfamethazine

    go.drugbank.com/drugs/DB01582
    ApprovedVet approvedWithdrawn

    A sulfanilamide anti-infective agent. It has a spectrum of antimicrobial action similar to other sulfonamides.

    Synonyms: N-(4,6-Dimethyl-2-pyrimidyl)sulfanilamide, N(1)-(4,6-Dimethyl-2-pyrimidyl)sulfanilamideMixtures: KHC TRIMETHOMIX 400/80MG/G PREMIX POWDER, Tylan 40 Sulfa-G Premix
  10. Drug

    Etoperidone

    go.drugbank.com/drugs/DB09194
    ApprovedWithdrawn

    Etoperidone is an atypical antidepressant introduced in Europe in 1977. … It is a phenylpiperazine-substituted triazole derivative with a composition that classifies it as an analog of tradozone and presents a similar pharmacological profile.